117 related articles for article (PubMed ID: 20839414)
1. Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes.
Perrone G; Morini S; Santini D; Rabitti C; Vincenzi B; Alloni R; Antinori A; Magistrelli P; Lai R; Cass C; Mackey JR; Coppola R; Tonini G; Onetti Muda A
Eur J Histochem; 2010; 54(3):e38. PubMed ID: 20839414
[TBL] [Abstract][Full Text] [Related]
2. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer.
Santini D; Perrone G; Vincenzi B; Lai R; Cass C; Alloni R; Rabitti C; Antinori A; Vecchio F; Morini S; Magistrelli P; Coppola R; Mackey JR; Tonini G
Ann Oncol; 2008 Apr; 19(4):724-8. PubMed ID: 18187485
[TBL] [Abstract][Full Text] [Related]
3. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J
Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587
[TBL] [Abstract][Full Text] [Related]
4. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy.
Murata Y; Hamada T; Kishiwada M; Ohsawa I; Mizuno S; Usui M; Sakurai H; Tabata M; Ii N; Inoue H; Shiraishi T; Isaji S
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):413-25. PubMed ID: 21898089
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.
Santini D; Vincenzi B; Fratto ME; Perrone G; Lai R; Catalano V; Cass C; Ruffini PA; Spoto C; Muretto P; Rizzo S; Muda AO; Mackey JR; Russo A; Tonini G; Graziano F
J Cell Physiol; 2010 May; 223(2):384-8. PubMed ID: 20082300
[TBL] [Abstract][Full Text] [Related]
6. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.
Kawada N; Uehara H; Katayama K; Nakamura S; Takahashi H; Ohigashi H; Ishikawa O; Nagata S; Tomita Y
J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):717-22. PubMed ID: 22426593
[TBL] [Abstract][Full Text] [Related]
7. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
[TBL] [Abstract][Full Text] [Related]
8. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy.
Okamura Y; Yasukawa S; Narimatsu H; Boku N; Fukutomi A; Konishi M; Morinaga S; Toyama H; Kaneoka Y; Shimizu Y; Nakamori S; Sata N; Yamakita K; Takahashi A; Kainuma O; Hishinuma S; Yamaguchi R; Nagino M; Hirano S; Yanagisawa A; Mori K; Uesaka K
Cancer Sci; 2020 Feb; 111(2):548-560. PubMed ID: 31778273
[TBL] [Abstract][Full Text] [Related]
9. Expression of gastric mucin MUC5AC and gastric transcription factor SOX2 in ampulla of vater adenocarcinoma: comparison between expression patterns and histologic subtypes.
Sanada Y; Yoshida K; Konishi K; Oeda M; Ohara M; Tsutani Y
Oncol Rep; 2006 May; 15(5):1157-61. PubMed ID: 16596179
[TBL] [Abstract][Full Text] [Related]
10. [Combined application of immunohistochemical markers to identify pathologic subtypes of ampullary carcinoma and its clinical significance].
Liu FF; Shen DH; Wang HL; Ma YT; Yuan F; Liu J; Chen L; Song QJ; Zhang YY
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):92-97. PubMed ID: 30695858
[No Abstract] [Full Text] [Related]
11. Prognostic Value of Excision Repair Cross-Complementing Gene 1, Dihydropyrimidine Dehydrogenase, and Human Equilibrative Nucleotide Transporter 1 Expression and Their Implications for Adjuvant Treatment in Patients With Ampullary Carcinoma.
Kawabata Y; Nishi T; Kidani A; Tajima Y
Pancreas; 2015 Aug; 44(6):937-44. PubMed ID: 25906447
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.
Santini D; Tonini G; Vecchio FM; Borzomati D; Vincenzi B; Valeri S; Antinori A; Castri F; Coppola R; Magistrelli P; Nuzzo G; Picciocchi A
J Clin Pathol; 2005 Feb; 58(2):159-65. PubMed ID: 15677536
[TBL] [Abstract][Full Text] [Related]
13. Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer.
Xiao JC; Zhang TP; Zhao YP
Hepatogastroenterology; 2013; 60(122):258-62. PubMed ID: 23574652
[TBL] [Abstract][Full Text] [Related]
14. Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up.
Zhou H; Schaefer N; Wolff M; Fischer HP
Am J Surg Pathol; 2004 Jul; 28(7):875-82. PubMed ID: 15223956
[TBL] [Abstract][Full Text] [Related]
15. COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters.
Perrone G; Santini D; Zagami M; Vincenzi B; Verzì A; Morini S; Borzomati D; Coppola R; Antinori A; Magistrelli P; Tonini G; Rabitti C
Virchows Arch; 2006 Sep; 449(3):334-40. PubMed ID: 16906389
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
17. Comparison between the location and the histomorphological/immunohistochemical characteristics of noninvasive neoplasms of the ampulla of Vater.
Yamamoto Y; Nemoto T; Okubo Y; Nihonyanagi Y; Ishiwatari T; Takuma K; Tochigi N; Okano N; Wakayama M; Igarashi Y; Shibuya K
Hum Pathol; 2014 Sep; 45(9):1910-7. PubMed ID: 25081540
[TBL] [Abstract][Full Text] [Related]
18. Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival.
Morini S; Perrone G; Borzomati D; Vincenzi B; Rabitti C; Righi D; Castri F; Manazza AD; Santini D; Tonini G; Coppola R; Onetti Muda A
Pancreas; 2013 Jan; 42(1):60-6. PubMed ID: 22889982
[TBL] [Abstract][Full Text] [Related]
19. Neoplasms of the ampulla of vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study.
Agoff SN; Crispin DA; Bronner MP; Dail DH; Hawes SE; Haggitt RC
Mod Pathol; 2001 Mar; 14(3):139-46. PubMed ID: 11266517
[TBL] [Abstract][Full Text] [Related]
20. Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1.
Wang H; Word BR; Lyn-Cook BD
Anticancer Res; 2011 Oct; 31(10):3171-80. PubMed ID: 21965724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
